Treatment
Semaglutide clinical trials
We’re tracking 144 recruiting studies that include Semaglutide, each written for real people, not researchers, below.
Recruiting studies
- NCT07651319RecruitingPhase 1/Phase 2
IL-2 and Semaglutide Treatment for Alzheimer's Disease
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
Houston, TexasAges 50–86 - NCT07018544Enrolling by invitation
Wegovy safety and effectiveness study in Korea
This study watches how Wegovy (semaglutide) works and its side effects when given by doctors to patients with obesity or overweight in South Korea. It is not testing a new drug, but collecting information from routine care.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05689372Enrolling by invitation
Ozempic safety and effectiveness after launch in type 2 diabetes
This study tracks how Ozempic works and whether it stays safe for people with type 2 diabetes in everyday clinic care in Korea. You join because your doctor decides you should start Ozempic, and the study mainly monitors outcomes.
Jeonlabuk-doAges 19 years+ - NCT05195944Enrolling by invitationPhase 4
Semaglutide versus sitagliptin after liver transplant for diabetes
This trial compares two diabetes medicines—semaglutide and sitagliptin—in people who have had a liver transplant and have type 2 diabetes (or diabetes after transplant). It’s looking to see which medicine works better and is safe for blood sugar control in the transplant setting.
Toronto, OntarioAges 18 years+ - NCT07779343Recruiting
Multidisciplinary support for adults living with obesity
This study tests a programme that combines medical, dietary, and behavioural support to help adults with obesity lose weight and improve their health. It looks at how well the programme works in everyday clinic settings.
AlgiersAges 18–65 - NCT07563699RecruitingPhase 1/Phase 2
Long-acting semaglutide injection for type 2 diabetes
This study tests a new long-acting form of semaglutide (a diabetes medication you may already take weekly) given as a depot injection. Researchers want to see if this new form is safe and works better for managing type 2 diabetes.
Tel AvivAges 18–64 - NCT07202247RecruitingPhase 2
Improving heart health in prostate cancer patients on hormone therapy
This study tests whether combining a time-restricted eating plan, a heart-healthy diet, and a weight-loss medication (GLP-1 receptor agonist) can help improve heart health and weight in men with prostate cancer who are receiving hormone therapy. It aims to reduce the risk of heart problems caused by hormone treatment.
Duarte, CaliforniaAges 30–79 - NCT07218354RecruitingPhase 3
Medication for reducing alcohol use in veterans
This study tests whether a medication (semaglutide) can help veterans reduce or stop drinking alcohol. It is for veterans who drink heavily and have alcohol use disorder, and who are interested in cutting down.
Long Beach, CaliforniaAges 18–80 - NCT07275697RecruitingPhase 4
Weight loss drug and heart ablation study for AFib
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
StockholmAges 18 years+ - NCT06975111RecruitingPhase 2/Phase 3
Improving health during menopause
This trial studies ways to help women during the late menopausal transition. It uses a smartphone app and telehealth visits to track your health and help you feel better.
Aurora, ColoradoAges 45–55 - NCT06318442Recruiting
Preventing steroid-induced diabetes with a GLP-1 drug
This study tests whether a GLP-1 medication (a type of drug that helps control blood sugar) can prevent diabetes caused by steroid treatments. It is for people who have prediabetes or mild diabetes and are about to receive a short course of steroids.
LondonAges 18 years+ - NCT06380426Recruiting
Semaglutide for teens and adults with genetic obesity
This study looks at how semaglutide works in real life for people with obesity caused by a single gene change. If you or your teenager have this type of obesity and are taking or about to start semaglutide, you may be able to join.
ParisAges 12 years+ - NCT05305794RecruitingPhase 3
Weekly Ozempic for insulin-dependent double diabetes
This trial tests whether a weekly injection called Ozempic (a GLP-1 medicine) can improve blood sugar control in adults who have type 1 diabetes plus higher-risk features for type 2 diabetes. If you qualify, the study will compare Ozempic against standard care to see if it helps your diabetes outcomes.
DijonAges 18 years+ - NCT07204249RecruitingPhase 2
Testing a diabetes drug to help stop meth use
This study tests whether a medication called 'Glutide' (a GLP-1 agonist, similar to drugs used for diabetes) can help people who want to stop or cut down on methamphetamine. It's for those with moderate to severe meth use disorder who have used meth on at least 15 of the past 30 days.
San Francisco, CaliforniaAges 18–65 - NCT07036172RecruitingPhase 3
Semaglutide vs Wegovy for weight loss in Chinese adults
This trial compares a semaglutide injection to the already-approved weight loss drug Wegovy in Chinese adults with obesity. It aims to see if the new option works just as well to help people lose weight.
BeijingAges 18–75 - NCT07743983RecruitingPhase 3
Study of BGM0504 in Early Type 2 Diabetes with Obesity
This trial tests an investigational drug, BGM0504, for people recently diagnosed with type 2 diabetes who also have obesity. It aims to see if the drug can help control blood sugar and support weight loss.
Nanjing, JiangsuAges 18–75 - NCT07428746RecruitingPhase 3
GLP-1 drug for bone health in older women with diabetes
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
Atlanta, GeorgiaAges 65 years+ - NCT06548490RecruitingPhase 2
Semaglutide for Opioid Use Disorder
This study tests whether a once-weekly injection of semaglutide (a GLP-1 receptor agonist) can reduce opioid use in people who are already on buprenorphine or methadone but still using opioids. It lasts about 19 weeks.
Baltimore, MarylandAges 18–75 - NCT05071898RecruitingPhase 1
Studying how genetics affect response to GLP-1 weight-loss drugs
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
Lancaster, PennsylvaniaAges 18–89 - NCT07724340RecruitingPhase 2
Study of AT673 plus semaglutide for type 2 diabetes and weight loss
This study tests a new medication called AT673 combined with semaglutide (Wegovy) to help people with type 2 diabetes and overweight or obesity lose weight and improve blood sugar. It is for people who have tried diet and exercise to lose weight but haven't had success.
Chandler, ArizonaAges 18 years+ - NCT06497595Recruiting
Lifestyle program to prevent muscle loss in older adults with diabetes on semaglutide
This trial tests whether a lifestyle program (diet and exercise) can help prevent muscle loss in people 65 and older with type 2 diabetes and obesity who are taking semaglutide. It may help you keep your strength and independence while losing weight.
Jerusalem, IsraelAges 65 years+ - NCT04990024Recruiting
Diet trial for people with obesity using semaglutide
This study compares different diets to see how they affect “arterial stiffness” (how hard the blood vessels are) in people with obesity who are starting semaglutide for weight management. It may help find a diet approach that improves heart and blood-vessel health while you use semaglutide.
Beirut, Riad El SolhAges 18–49 - NCT05119179RecruitingPhase 4
Testing how genetics affect GLP-1 response in prediabetes
This study looks at how your genes may change how well a GLP-1–type medicine works to improve prediabetes. It focuses on adults at higher risk of developing diabetes, especially people of Mexican-American background.
Brownsville, TexasAges 18 years+ - NCT05173714RecruitingPhase 2
Sit Less and Move More program for people with CKD
This Phase 2 study tests a program to help people with chronic kidney disease (CKD) sit less and move more, plus a medication (semaglutide) for those who qualify. It may help improve health and day-to-day activity while monitoring safety closely.
Stanford, CaliforniaAges 20 years+
Common questions
- Are there clinical trials studying Semaglutide?
- Yes. Clin2 currently lists 144 recruiting studies that include Semaglutide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Semaglutide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Semaglutide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Semaglutide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.